13,875 Shares in GeneDx Holdings Corp. (NASDAQ:WGS) Acquired by Alpha DNA Investment Management LLC

Alpha DNA Investment Management LLC acquired a new stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 13,875 shares of the company’s stock, valued at approximately $363,000.

Several other institutional investors and hedge funds have also recently modified their holdings of WGS. Acadian Asset Management LLC purchased a new stake in shares of GeneDx in the second quarter worth about $34,000. nVerses Capital LLC purchased a new stake in shares of GeneDx during the 2nd quarter worth approximately $50,000. Thompson Davis & CO. Inc. boosted its position in shares of GeneDx by 20.8% during the 1st quarter. Thompson Davis & CO. Inc. now owns 24,094 shares of the company’s stock valued at $220,000 after acquiring an additional 4,150 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of GeneDx by 36.1% in the second quarter. American Century Companies Inc. now owns 17,258 shares of the company’s stock valued at $451,000 after purchasing an additional 4,573 shares in the last quarter. Finally, Rhumbline Advisers increased its position in GeneDx by 8,096.4% in the second quarter. Rhumbline Advisers now owns 18,360 shares of the company’s stock worth $480,000 after purchasing an additional 18,136 shares during the last quarter. Institutional investors own 61.72% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on WGS shares. Craig Hallum increased their price objective on shares of GeneDx from $43.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. Jefferies Financial Group began coverage on GeneDx in a research report on Monday, June 3rd. They issued a “hold” rating and a $21.00 price target for the company. Wells Fargo & Company assumed coverage on GeneDx in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $34.00 price objective on the stock. The Goldman Sachs Group lifted their target price on GeneDx from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Finally, BTIG Research increased their price target on GeneDx from $35.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

GeneDx Trading Down 5.7 %

WGS opened at $36.84 on Thursday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.22 and a current ratio of 2.38. The stock’s 50 day moving average price is $33.97 and its 200-day moving average price is $24.34. GeneDx Holdings Corp. has a one year low of $1.16 and a one year high of $43.32. The stock has a market cap of $962.33 million, a price-to-earnings ratio of -7.11 and a beta of 2.29.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Tuesday, July 30th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.15. GeneDx had a negative return on equity of 22.71% and a negative net margin of 48.21%. The company had revenue of $70.51 million for the quarter, compared to the consensus estimate of $58.90 million. On average, equities analysts forecast that GeneDx Holdings Corp. will post -0.75 EPS for the current year.

Insider Buying and Selling

In other GeneDx news, CFO Kevin Feeley sold 895 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $33.33, for a total value of $29,830.35. Following the transaction, the chief financial officer now directly owns 39,910 shares in the company, valued at approximately $1,330,200.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other GeneDx news, CFO Kevin Feeley sold 895 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $33.33, for a total value of $29,830.35. Following the completion of the sale, the chief financial officer now directly owns 39,910 shares in the company, valued at approximately $1,330,200.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Opko Health, Inc. sold 50,000 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $26.63, for a total value of $1,331,500.00. Following the transaction, the insider now owns 3,508,603 shares in the company, valued at approximately $93,434,097.89. The disclosure for this sale can be found here. Insiders have sold 743,868 shares of company stock valued at $24,114,996 in the last 90 days. Company insiders own 28.10% of the company’s stock.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.